Adalimumab-induced lichenoid drug eruption

Tumor necrosis factor [TNF]- alpha inhibitors are being widely and increasingly used for the management of a spectrum of rheumatologic diseases that are refractory to conventional disease modifying anti-rheumatic drugs. Various cutaneous side effects have been reported after treatment with TNF- alpha inhibitors. We present a case report of a 26-year- old male patient who developed a lichenoid drug eruption few months after the initiation of adalimumab for the manage- ment of Crohn's disease. We also highlight the clinical and histopathologic differences between lichenoid drug eruptions and idiopathic lichen planus

Drug-induced linear IgA bullous dermatosis simulating toxic epidermal necrolysis

Linear IgA bullous dermatosis [LAD] is an autoimmune subepidermal blistering disorder. LAD may be either idiopathic or drug related; the most common drug being vancomycin. The clinical presentations of both idiopathic and drug-related LAD are variable and may mimic other blistering disorders. We report a case of a 76-year-old man known to have a renal cell carcinoma who presented a vancomycin-induced LAD that clinically mimicked toxic epidermal necrolysis [TEN]